Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aTac-BEAM Conditioning for AHCT in Relapsed/Refractory Hodgkin Lymphoma
NCT04871607Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Nov 2021
- Primary completion
- Oct 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium Y 90-labeled basiliximab in Hodgkin lymphoma (HL), sponsored by City of Hope. Started Nov 2021; status: recruiting.
02
Drugs
yttrium Y 90-labeled basiliximab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04871607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871607.